PetVivo (OTC: PETV) Disrupts $39B Pet Health Market | Spring OsteoCushion & PRP Innovation
For biotech investors, veterinary professionals, and animal health innovators — this New to The Street: Investor Event Special interview features John Lai, CEO of PetVivo Holdings (OTC: PETV), presenting the company’s breakthrough technologies in the $39 billion companion animal care market.
PetVivo’s flagship product, Spryng™ with OsteoCushion Technology, is a naturally derived veterinary medical device that restores joint mechanics, functioning like an extracellular matrix to repair cartilage defects. Unlike NSAIDs and steroids—which only mask pain and can worsen cartilage degradation—Spryng addresses the root cause of osteoarthritis. The product provides up to 12 months of relief, integrates naturally into the synovium, and requires no FDA animal-side studies due to its human medical device designation.
PetVivo’s second innovation, Precise PRP, is the only PRP product reviewed by the FDA for safety. It requires no centrifuge, no blood draw, and delivers a guaranteed 4 million platelets per dose, saving veterinarians 30+ minutes per procedure and providing highly consistent regenerative results.
Key Highlights
Distributed by five of the largest vet distributors, including MWI, Covetrus, Vetco, Patterson, Clipper
Recently expanded into Mexico and the UK, with the rest of the EU expected within 6–9 months
Over 12,000 animals treated, with hundreds of documented case studies across dogs and performance horses
Only product allowed by HISA (Horse Integrity and Safety Authority) without triggering hydrogel injection racing bans — specifically named in regulations
Strong IP portfolio: 12 U.S. patents, 19 foreign patents
Market tailwinds: 80{d450b60efc35a2e17361b5d57bc194208ff1ac62c46bd45a026f4271e6a4dcc4} of dogs have osteoarthritis by age 8; U.S. pet care spending rising from $147B (2023) to $151B (2024)
New AI platform (agentic swarming) launching within 30 days to help clinics increase margins and cut customer acquisition cost by 90{d450b60efc35a2e17361b5d57bc194208ff1ac62c46bd45a026f4271e6a4dcc4}
Partnered with Veterinary Growth Partners (7,300 clinics), accelerating national adoption.
PetVivo is also preparing for human clinical studies aimed at delaying or preventing joint replacement surgeries — a market worth $11B in the U.S. and $33B globally.
With powerful clinical results, expanding distribution, artificial intelligence partnerships, and global market access, PetVivo is positioned as a category-defining leader in veterinary regenerative therapeutics.
#NewToTheStreet #PetVivo #PETV #Spryng #OsteoCushion #PRP #RegenerativeMedicine #VeterinaryCare #AnimalHealth #PetCareMarket #Osteoarthritis #DogHealth #HorseHealth #HISA #FDAApprovedDevice #BiotechInvesting #VetTech #CompanionAnimals #JointHealth #VeterinaryInnovation #AnimalWellness #AIinHealthcare #InvestorInsights #PetIndustry #FunctionalRegeneration
